The SARS-CoV-2 main protease as drug target

Bioorg Med Chem Lett. 2020 Sep 1;30(17):127377. doi: 10.1016/j.bmcl.2020.127377. Epub 2020 Jul 2.

Abstract

The unprecedented pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is threatening global health. The virus emerged in late 2019 and can cause a severe disease associated with significant mortality. Several vaccine development and drug discovery campaigns are underway. The SARS-CoV-2 main protease is considered a promising drug target, as it is dissimilar to human proteases. Sequence and structure of the main protease are closely related to those from other betacoronaviruses, facilitating drug discovery attempts based on previous lead compounds. Covalently binding peptidomimetics and small molecules are investigated. Various compounds show antiviral activity in infected human cells.

Keywords: Antivirals; COVID-19; Coronavirus; Peptidomimetics; Protease inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / pharmacology*
  • Betacoronavirus / drug effects*
  • Betacoronavirus / enzymology
  • Cell Line
  • Coronavirus 3C Proteases
  • Cysteine Endopeptidases / chemistry
  • Cysteine Proteinase Inhibitors / pharmacokinetics
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Drug Discovery
  • Humans
  • Peptidomimetics / pharmacokinetics
  • Peptidomimetics / pharmacology
  • SARS-CoV-2
  • Substrate Specificity
  • Viral Nonstructural Proteins / antagonists & inhibitors*
  • Viral Nonstructural Proteins / chemistry

Substances

  • Antiviral Agents
  • Cysteine Proteinase Inhibitors
  • Peptidomimetics
  • Viral Nonstructural Proteins
  • Cysteine Endopeptidases
  • Coronavirus 3C Proteases